Proteomic analysis of urinary upper gastrointestinal cancer markers

Proteomics - Clinical Applications

Volumn 5, Issue 5-6, 2011, Pages 289-299

  Husi, Holger ^a   Stephens, Nathan ^a   Cronshaw, Andrew ^a   Macdonald, Alisdair ^a   Gallagher, Iain ^a   Greig, Carolyn ^a   Fearon, Kenneth C H ^a   Ross, James A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

SELDI TOF; Upper gastrointestinal cancer; Urine biomarker

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN PRECURSOR; ALPHA 1 ANTITRYPSIN PRECURSOR; MOLECULAR MARKER; PEPTIDE; PROTEIN S 100 A12; PROTEIN S 100 A6; PROTEIN S 100 A9; PROTEIN S 100 P; SH3 DOMAIN BINDING GLUTAMIC ACID RICH LIKE PROTEIN 3; TRYPSIN 3 PRECURSOR; TUMOR MARKER; UBIQUITIN; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; COMPUTER PROGRAM; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROTEIN DATABASE; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UPPER GASTROINTESTINAL TRACT; URINALYSIS; VALIDITY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; UPPER GASTROINTESTINAL TRACT; YOUNG ADULT;

EID: 79957622297     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000107     Document Type: Article

References (58)

1. Sweed, M. R., Edmonson, D., Cohen, S. J., Tumors of the esophagus, gastroesophageal junction, and stomach. Semin. Oncol. Nurs. 2009, 25, 61-75.
2. Lee, W., Patel, J. H., Lockhart, A. C., Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin. Investig. Drugs 2009, 18, 1351-1364.
3. Valverde, C. M., Macarulla, T., Casado, E., Ramos, F. J., Novel targets in gastric and esophageal cancer. Crit. Rev. Oncol. Hematol. 2006, 59, 128-138.
4. Grote, T., Siwak, D. R., Fritsche, H. A., Joy, C. et al., Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 2008, 8, 3051-3060.
5. Lee, G., Ge, B., Huang, T. K., Zheng, G. et al., Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients. Cancer Biomark. 2010, 6, 111-117.
6. Lee, G., Laflamme, E., Chien, C. H., Ting, H. H., Molecular identity of a pan cancer marker, CA215. Cancer Biol. Ther. 2008, 7, 2007-2014.
7. Shami, V. M., Sundaram, V., Stelow, E. B., Conaway, M. et al., The level of carcinoembryonic antigen and the presence of mucin as predictors of cystic pancreatic mucinous neoplasia. Pancreas 2007, 34, 466-469.
8. Hao, Y., Yu, Y., Wang, L., Yan, M. et al., IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J. Proteome Res. 2008, 7, 3668-3677.
9. Hardt, P. D., Ewald, N., Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy. Expert Rev. Mol. Diagn. 2008, 8, 579-585.
10. Gaber, A., Johansson, M., Stenman, U. H., Hotakainen, K. et al., High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br. J. Cancer 2009, 100, 1540-1548.
11. Ljungberg, B., Prognostic markers in renal cell carcinoma. Curr. Opin. Urol. 2007, 17, 303-308.
12. Higgins, J. P., Gene array studies in renal neoplasia. Sci. World J. 2006, 6, 502-511.
13. Adachi, J., Kumar, C., Zhang, Y., Olsen, J. V., Mann, M., The human urinary proteome contains more than 1500 proteins including a large proportion of membranes proteins. Genome Biol. 2006, 7, R80.1-R80.16.
14. Good, D. M., Thongboonkerd, V., Novak, J., Bascands, J. L. et al., Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J. Proteome Res. 2007, 6, 4549-4555.
15. Ke, E., Patel, B. B., Liu, T., Li, X. M. et al., Proteomic analyses of pancreatic cyst fluids. Pancreas 2009, 38, e33-e42.
16. Simonsen, A. H., Yip, T. T., Hogdall, E., Fung, E. T. et al., Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet. Gynecol. Scand. 2009, 88, 18-26.
17. Tsui, K. H., Tang, P., Lin, C. Y., Chang, P. L. et al., Bikunin loss in urine as useful marker for bladder carcinoma. J. Urol. 2010, 183, 339-344.
18. Chen, Y. T., Yu, J. S., Chen, C. L., Chen, H. W. et al., Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J. Proteome Res. 2010, 9, 5803-5815.
19. Tan, L. B., Chen, K. T., Yuan, Y. C., Liao, P. C., Guo, H. R., Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis. World J. Urol. 2010, 28, 117-122.
20. Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L. et al., Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J. Transl. Med. 2009, 7, 105.
21. Takano, S., Sogawa, K., Yoshitomi, H., Shida, T. et al., Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br. J. Cancer 2010, 103, 223-231.
22. Xue, A., Scarlett, C. J., Chung, L., Butturini, G. et al., Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 2010, 103, 391-400.
23. Schröder, C., Jacob, A., Tonack, S., Radon, T. P. et al., Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol. Cell. Proteomics 2010, 9, 1271-1280.
24. Kistler, A. D., Mischak, H., Poster, D., Dakna, M. et al., Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009, 76, 89-96.
25. Metzger, J., Kirsch, T., Schiffer, E., Ulger, P. et al., Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010, 78, 1252-1262.
26. Good, D. M., Zurbig, P., Argiles, A., Bauer, H. W. et al., Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics 2010, 9, 2424-2437.
27. Collins, M. O., Yu, L., Choudhary, J. S., Analysis protein complexes by 1D-SDS-PAGE and tandem mass spectrometry. Nat. Protoc. 2008, doi:10.1038/nprot.2008.123.
28. Husi, H., Ward, M. A., Choudhary, J. S., Blackstock, W. P., Grant, S. G. N., Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 2000, 3, 633-635.
29. Caffrey, R. E., A review of experimental design best practices for proteomics based biomarker discovery: focus on SELDI-TOF. Methods Mol. Biol. 2010, 641, 167-183.
30. Okamoto, A., Yamamoto, H., Imai, A., Hatakeyama, S. et al., Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions. Oncol. Rep. 2009, 21, 73-79.
31. Gagnon, A., Shi, Q., Ye, B., Surface-enhanced laser desorption/ionization mass spectrometry for protein and Peptide profiling of body fluids. Methods Mol. Biol. 2008, 441, 41-56.
32. Roelofsen, H., Alvarez-Llamas, G., Schepers, M., Landman, K., Vonk, R. J., Proteomics profiling of urine with surface enhanced laser desorption/ionization time of flight mass spectrometry. Proteome Sci. 2007, 5, 2.
33. Dougan, M., Dranoff, G., Inciting inflammation: the RAGE about tumor promotion. J. Exp. Med. 2008, 205, 267-270.
34. Leclerc, E., Heizmann, C. W., Vetter, S. W., RAGE and S100 protein transcription levels are highly variable in human melanoma tumors and cells. Gen. Physiol. Biophys. 2009, 28, F65-F75.
35. Hsieh, H. L., Schäfer, B. W., Sasaki, N., Heizmann, C. W., Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem. Biophys. Res. Commun. 2003, 307, 375-381.
36. Smalley, D. M., Sheman, N. E., Nelson, K., Theodorescu, D., Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J. Proteome Res. 2008, 7, 2088-2096.
37. Kreunin, P., Zhao, J., Rosser, C., Urquidi, V., Lubman, D. M., Goodison, S., Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J. Proteome Res. 2007, 6, 2631-2639.
38. Wang, X. H., Zhang, L. H., Zhong, X. Y., Xing, X. F. et al., S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am. J. Pathol. 2010, 177, 586-597.
39. Ishii, A., Suzuki, M., Satomi, K., Kobayashi, H. et al., Increased cytoplasmic S100A6 expression is associated with pulmonary adenocarcinoma progression. Pathol. Int. 2009, 59, 623-630.
40. Leach, S. T., Yang, Z., Messina, I., Song, C. et al., Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand. J. Gastroenterol. 2007, 42, 1321-1331.
41. Su, Y. J., Xu, F., Yu, J. P., Yue, D. S. et al., Up-regulation of the expression of S100A8 and S100A9 in lung adenocarcinoma and its correlation with inflammation and other clinical features. Chin. Med. J. (Engl). 2010, 123, 2215-2220.
42. Gonçalves, A., Charafe-Jauffret, E., Bertucci, F., Audebert, S. et al., Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol. Cell. Proteomics 2008, 7, 1420-1433.
43. Minami, S., Sato, Y., Matsumoto, T., Kageyama, T. et al., Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins. Cancer Genom. Proteomics 2010, 7, 181-189.
44. Kim, H. K., Reyzer, M. L., Choi, I. J., Kim, C. G. et al., Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J. Proteome Res. 2010, 9, 4123-4130.
45. Karl, J., Wild, N., Tacke, M., Andres, H. et al., Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin. Gastroenterol. Hepatol. 2008, 6, 1122-1128.
46. Dowen, S. E., Crnogorac-Jurcevic, T., Gangeswaran, R., Hansen, M. et al., Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am. J. Pathol. 2005, 166, 81-92.
47. Zelvyte, I., Wallmark, A., Piitulainen, E., Westin, U., Janciauskiene, S., Increased plasma levels of serine proteinase inhibitors in lung cancer patients. Anticancer Res. 2004, 24, 241-247.
48. El-Akawi, Z. J., Abu-Awad, A. M., Sharara, A. M., Khader, Y., The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients. Neuro. Endocrinol. Lett. 2010, 31, 113-116.
49. Chung, J. C., Oh, M. J., Choi, S. H., Bae, C. D., Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J. Surg. 2008, 78, 245-251.
50. Miller, J. C., Zhou, H., Kwekel, J., Cavallo, R. et al., Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003, 3, 56-63.
51. Yu, K. H., Rustgi, A. K., Blair, I. A., Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J. Proteome Res. 2005, 4, 1742-1751.
52. Gonçalves, A., Charafe-Jauffret, E., Bertucci, F., Audebert, S. et al., Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol. Cell. Proteomics 2008, 7, 1420-1433.
53. Henshall, S. M., Horvath, L. G., Quinn, D. I., Eggleton, S. A. et al., Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J. Natl. Cancer Inst. 2006, 98, 1420-1424.
54. Irmak, S., Tilki, D., Heukeshoven, J., Oliveira-Ferrer, L. et al., Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005, 5, 4296-4304.
55. Khalil, A. A., Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007, 98, 201-213.
56. Rosendahl, J., Teich, N., Kovacs, P., Szmola, R. et al., Complete analysis of the human mesotrypsinogen gene (PRSS3) in patients with chronic pancreatitis. Pancreatology 2010, 10, 243-249.
57. Alaiya, A., Al-Mohanna, M., Linder, S., Clinical cancer proteomics: promises and pitfalls. J. Proteome Res. 2005, 4, 1213-1222.
58. Mischak, H., Allmaier, G., Apweiler, R., Attwood, T. et al., Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2010, 2, 46ps42.